首页 › 急性髓系白血病 › 北卡罗来纳州

北卡罗来纳州的急性髓系白血病临床试验

北卡罗来纳州有 43 项针对急性髓系白血病的研究正在招募参与者。

北卡罗来纳州的城市

官方研究文本（英文）

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

AdventHealth Infusion Center Asheville, Asheville
Southeastern Medical Oncology Center-Clinton, Clinton
AdventHealth Infusion Center Haywood, Clyde
以及另外 6 项

招募中观察性研究欢迎健康志愿者

40 至 75 岁 · 所有性别 · 更新于 2026年10月2日 · NCT05334069

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

Wake Forest University Health Sciences, Winston-Salem

招募中1 期

18 岁及以上 · 所有性别 · 更新于 2026年10月1日 · NCT06484062

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Carolinas Medical Center/Levine Cancer Institute, Charlotte
Novant Health Presbyterian Medical Center, Charlotte
Duke University Medical Center, Durham
以及另外 3 项

招募中2 期

18 至 59 岁 · 所有性别 · 更新于 2026年9月28日 · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Atrium Health, Charlotte
Novant Health Charlotte, Charlotte
Carolina Oncology Specialists, Charlotte
以及另外 2 项

招募中3 期

18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT06852222

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

UNC Lineberger Comprehensive Cancer Center, Chapel Hill
Carolinas Medical Center/Levine Cancer Institute, Charlotte
Novant Health Presbyterian Medical Center, Charlotte
以及另外 5 项

招募中2 期

18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT05564390

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Carolinas Medical Center/Levine Cancer Institute, Charlotte
Duke University Medical Center, Durham
East Carolina University, Greenville
以及另外 1 项

招募中2 期

18 岁及以上 · 所有性别 · 更新于 2026年9月22日 · NCT06317649

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Carolinas Medical Center/Levine Cancer Institute, Charlotte
Duke University Medical Center, Durham
East Carolina University, Greenville
以及另外 1 项

招募中2 期

18 岁及以上 · 所有性别 · 更新于 2026年9月22日 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

Carolinas Medical Center/Levine Cancer Institute, Charlotte
Duke University Medical Center, Durham
East Carolina University, Greenville
以及另外 1 项

招募中2 期

18 至 59 岁 · 所有性别 · 更新于 2026年9月22日 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Mission Hospital, Asheville
UNC Lineberger Comprehensive Cancer Center, Chapel Hill
Carolinas Medical Center/Levine Cancer Institute, Charlotte
以及另外 4 项

招募中3 期

6 Months – 21 Years · 所有性别 · 更新于 2026年9月17日 · NCT04293562

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Duke University Medical Center, Durham

招募中1/2 期

30 Days · 所有性别 · 更新于 2026年9月16日 · NCT04065399

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

Novant Health Clinical Research, Charlotte
East Carolina University, Greenville

招募中2 期

18 岁及以上 · 所有性别 · 更新于 2026年9月16日 · NCT06824168

Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

University of North Carolina at Chapel Hill, Chapel Hill

招募中1 期

18 岁及以上 · 所有性别 · 更新于 2026年9月14日 · NCT06846606

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

UNC School of Medicine, Division of Hematology, Chapel Hill

招募中1/2 期

12 岁及以上 · 所有性别 · 更新于 2026年9月3日 · NCT04588922

A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies

Novant Health Weisiger Cancer Institute, Charlotte

招募中观察性研究

0 岁及以上 · 所有性别 · 更新于 2026年9月2日 · NCT07154823

Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax

Atrium Health Wake Forest Baptist Medical Center, Winston-Salem

招募中2 期

18 岁及以上 · 所有性别 · 更新于 2026年9月2日 · NCT07471841

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

US-Chapel Hill-UNCNORTHCAROLINA, Chapel Hill

招募中3 期

18 岁及以上 · 所有性别 · 更新于 2026年9月2日 · NCT06652438

A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

UNC Lineberger Comprehensive Cancer Center, Chapel Hill
Carolinas Medical Center/Levine Cancer Institute, Charlotte
Wake Forest University Health Sciences, Winston-Salem

招募中1 期

18 至 75 岁 · 所有性别 · 更新于 2026年8月25日 · NCT05886049

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Mission Hospital, Asheville
UNC Lineberger Comprehensive Cancer Center, Chapel Hill
Carolinas Medical Center/Levine Cancer Institute, Charlotte
以及另外 4 项

招募中1/2 期

22 岁及以下 · 所有性别 · 更新于 2026年8月25日 · NCT04726241

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

University of North Carolina, Chapel Hill, Chapel Hill
Duke University Medical Center, Durham

招募中3 期

18 岁及以上 · 所有性别 · 更新于 2026年8月20日 · NCT07007312

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Atrium Health Levine Cancer Center, Charlotte

招募中1 期

18 岁及以上 · 所有性别 · 更新于 2026年8月20日 · NCT06001788

ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

University of North Carolina at Chapel Hill, Chapel Hill

招募中1 期

18 岁及以上 · 所有性别 · 更新于 2026年8月18日 · NCT06656494

Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML

Levine Cancer Institute, Charlotte
Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem

招募中观察性研究

18 岁及以上 · 所有性别 · 更新于 2026年7月24日 · NCT06580106

ONC-LEUK-2406: The Impact of Systematic Financial Navigation in Acute Myeloid Leukemia

Levine Cancer Insitute, Charlotte
Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem

招募中

18 至 64 岁 · 所有性别 · 更新于 2026年7月23日 · NCT06945042

Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

Research Site, Chapel Hill
Research Site, Durham

招募中1/2 期

16 岁及以上 · 所有性别 · 更新于 2026年7月20日 · NCT07155226

Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

University of North Carolina at Chapel Hill, Chapel Hill
Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem

招募中2 期

18 岁及以上 · 所有性别 · 更新于 2026年7月10日 · NCT05442216

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

University of North Carolina at Chapel Hill, Chapel Hill
Levine Children's Hospital, Charlotte
Duke University Medical Center, Durham

招募中观察性研究

所有年龄段 · 所有性别 · 更新于 2026年7月6日 · NCT01351545

A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers

University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill
Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Section of Hematology/Oncology, Winston-Salem

招募中

60 岁及以上 · 所有性别 · 更新于 2026年7月6日 · NCT06697600

Registry of Older Patients With Cancer

Seby B. Jones Cancer Center, Boone
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
East Carolina University, Greenville
以及另外 4 项

招募中观察性研究

65 岁及以上 · 所有性别 · 更新于 2026年6月29日 · NCT01137825